Is your company working on a new instrument to measure patient-reported outcomes as part of a device trial? Then it might want to collaborate with patient groups or health professional associations as part of the development process, the US Food and Drug Administration recommends in a new draft guidance document.
The guidance, dated 31 August, offers the agency’s views on selecting, developing and adapting patient-reported outcome (PRO) instruments for use in medical device evaluation